Since carbendazim should be approved under the terms of Directive 98/8/EC, taking into account those properties, the period of approval should be considerably shorter than 10 years in accordance with the latest practice established under that Directive. In addition, since carbendazim has benefitted from the transitional period provided for in Article 89 of Regulation (EU) No 528/2012 since 14 May 2000 and has been under peer review since 2 August 2013, and with the view to examine at Union level as soon as possible in the context of a potential renewal of approval whether the conditions of Article 5(2) of Regulation (EU) No 528/2012 can be satisfied for carbendazim, the period of approval should be three years.
Recital 9, Regulation (EU) 2021/348
In forcesince 25 Feb 2021cited 1×
Judgment of the General Court (Ninth Chamber) of 17 January 2024. Troy Chemical Company BV and Troy Corp. v European Commission.Decision
In that regard, the consideration, in recital 9 of the contested regulation, of the need to examine as soon as possible, at EU level, in the context of a possible renewal of the approval of carbendazim, whether that substance fulfilled the …
17 Jan 2024 · 62021TJ0297
Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012…895Law
- celex=31998L0008
- num:eu=1998/8